Presentation of Cevira® Phase 2b Results

Published: 5 December 2012Medical congresses & eventsMedical InformationFinancial Investment & Stock

Oslo, Norway, 5 December 2012

Photocure will host an audio webcast today at 15.00 CET / 14.00 GMT / 09.00 EST to present the Cevira phase 2b results.

It will be possible to follow the presentation through

Please find the presentation enclosed.

CFO Erik Dahl
Tel: +47 450 55 000, e-mail:

M: Communications
Mary Clark, Amber Bielecka, Hollie Vile
Tel: +44 207920 2361, Email:

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

All trademarks mentioned in this release are protected by law and registered trademarks of Photocure ASA.


This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events